VERAXA Biotech (NASDAQ: VRXA) has entered into a collaboration with Ardigen S.A., an AI-driven bioinformatics company, to support the development of its BiTAC pipeline of T-cell engagers and future antibody-drug conjugates. The partnership aims to develop AI-enabled tools to identify and prioritize synergistic dual-target combinations for VERAXA’s BiTAC platform, which is designed to improve tumor targeting while reducing off-target toxicity, according to a press release issued July 13, 2026.
VERAXA stated that integrating artificial intelligence into its research and development strategy could enhance target selection by analyzing large preclinical and clinical datasets, including programs that demonstrated efficacy but failed because of toxicity. The company believes the collaboration will strengthen development of precision oncology therapies and improve long-term drug development success rates.
The BiTAC platform is a proprietary technology that uses bispecific T-cell engagers to direct the immune system to attack cancer cells. By leveraging Ardigen’s AI capabilities, VERAXA hopes to more efficiently identify optimal dual-target combinations that maximize tumor killing while minimizing harm to healthy tissues. This approach addresses a common challenge in oncology where promising therapies are often limited by toxicity.
This news is important because it represents a growing trend in the pharmaceutical industry to incorporate artificial intelligence into drug discovery and development. AI can process vast amounts of data to uncover patterns that human researchers might miss, potentially reducing the time and cost of bringing new cancer treatments to market. For patients, this could lead to more effective therapies with fewer side effects. For the industry, it signals a shift toward data-driven precision medicine.
VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. The company is building a pipeline of next-generation antibody-based therapeutics, including bispecific T-cell engagers, bispecific ADCs, and other innovative formats.
The full press release is available at https://ibn.fm/GLFg2. For the latest news and updates relating to VRXA, visit the company’s newsroom at https://ibn.fm/VRXA.
Forward-looking statements in the release are subject to risks and uncertainties as detailed in the company’s filings with the SEC, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The company undertakes no duty to update this information unless required by law.
